National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, (An Institute of National Importance, Government of India), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opposite Air Force Station, Gandhinagar, Gujarat-382355, India.
School of Pharmacy & Technology Management, SVKM's NMIMS, Shirpur, 425405, India.
Curr Pharm Des. 2018;24(23):2632-2643. doi: 10.2174/1381612824666180807113948.
RNA interference (RNAi), as a novel technique in which RNA molecules limit or silence the gene expression, is currently a hot research topic for producing novel therapeutic materials for challenging diseases. In the development of RNAi-based therapies, nanoscale particles, with a varying diameter along with facile modification methods that can mediate effective RNAi with targeting potential, are gaining wide interest. The nanotechnology itself has tremendous potential in the field of healthcare, especially for the development of better pharmaceuticals. Nano-enabled delivery has shown great success in the delivery of RNAi based therapeutics to specific locations in the body. Especially, siRNAs show great potential for use in nucleic acid therapeutics because of their potent and specific RNAi-triggering activity. This review summarizes the advanced nanocarriers such as solid lipid nanoparticles, gold nanoparticles, silver nanoparticles, iron oxide nanoparticles, polymeric nanoparticles, nanotransformers and curdlan nanoparticles with special emphasis on various aspects of siRNA-based therapeutics.
RNA 干扰 (RNAi) 作为一种新型的 RNA 分子限制或沉默基因表达的技术,目前是针对挑战性疾病生产新型治疗材料的热门研究课题。在基于 RNAi 的治疗方法的开发中,纳米级颗粒由于具有不同的直径以及可以介导具有靶向潜力的有效 RNAi 的简便修饰方法,引起了广泛的关注。纳米技术本身在医疗保健领域具有巨大的潜力,特别是在开发更好的药物方面。纳米技术使 RNAi 治疗剂在体内特定部位的递呈取得了巨大的成功。特别是,由于其强大而特异的 RNAi 触发活性,siRNA 在核酸治疗中具有巨大的应用潜力。本综述总结了先进的纳米载体,如固体脂质纳米粒、金纳米粒、银纳米粒、氧化铁纳米粒、聚合物纳米粒、纳米变形虫和卡拉胶纳米粒,并特别强调了基于 siRNA 的治疗的各个方面。
Curr Pharm Des. 2018
Nanomedicine (Lond). 2019-8-1
Acc Chem Res. 2019-5-28
J Control Release. 2016-5-20
Transl Res. 2019-7-22
Curr Pharm Des. 2015
Nanotechnology. 2018-1-5
Drug Des Devel Ther. 2024